Pharmaceutical Research and Manufacturers of America reported Wednesday that 444 drugs intended to treat neurological disorders are in clinical development or being reviewed by the FDA. "Despite the incredible complexity of neurological disorders, biopharmaceutical scientists have delivered significant advances for patients in recent years, including new medicines for multiple sclerosis and Huntington's diseases," said John J. Castellani, PhRMA's president and CEO.
Nearly 450 drugs for neurological disorders are in the pipeline
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||